The effect of treatment with anti‐interleukin‐17 in patients with allergic contact dermatitis
Abstract
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Studies examining the anti-IL-17 biologic secukinumab revealed it to be ineffective against ACD.
“Of note, studies examining the anti-IL-17 biologic secukinumab revealed it to be ineffective against ACD, 10,11”
From Dupilumab for Allergic Contact Dermatitis: An Overview of Its Use and Impact on Patch Testing. (2022) · cites this paper as [11]
Cited by
Sorted by citations
Dupilumab for Allergic Contact Dermatitis: An Overview of Its Use and Impact on Patch Testing.
Johnson, H. (2022) · Current Psychiatry · doi:10.12788/cutis.0519 · Cited by 20 · see citing works
- Authors
- Todberg, T., Zachariae, C., Krustrup, D., & Skov, L.
- Affiliations
- University of Copenhagen (DK)
- Corresponding author
- Todberg, Tanja
- Venue
- Contact Dermatitis
- Publisher
- Wiley
- Published
- 2018-05-03
- Volume
- 78
- Issue
- 6
- Pages
- 431-432
- ISSN
- 0105-1873 (ISSN-L)
- 1600-0536
- OpenAlex
- W2800242803
- Cited by
- 21
- References
- 0
- Citations by year
- 2025: 5 · 2024: 1 · 2023: 1 · 2022: 3 · 2021: 3 · 2020: 6 · 2018: 2
- FWCI
- 2.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Contact Dermatitis (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Topics
- Health Sciences › Medicine › Dermatology › Contact Dermatitis and Allergies
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Keywords
- IL-17, allergic contact dermatitis, IL-17 inhibition, treatment efficacy
- MeSH terms
- Aged, Antibodies, Monoclonal, Dermatologic Agents, Female, Humans, Male, Middle Aged, Treatment Outcome, Dermatitis, Allergic Contact, Interleukin-17, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
